Navigation Links
Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
Date:11/6/2012

ing," Steven R. Smith, M.D., scientific director of the Florida Hospital-Sanford Burnham Translational Research Institute for Metabolism and Diabetes[1], said.  "This new trial will evaluate how the effects of this novel therapy extend with longer treatment in patients with type 2 diabetes, an important obesity-related co-morbid condition, and will be an important scientific milestone in shaping its use in the treatment of obesity and its related conditions." 

Results from the next clinical development phase are anticipated to be available in June 2013.  For more information about the study, visit ClinicalTrials.gov.

About Fat Metabolism

Research continues to show that obese and lean individuals metabolize fat differently.  Studies indicate that once a person becomes obese, the body undergoes certain metabolic changes and is "programmed" to create and store more fat, making it much more difficult to reduce body weight.  These metabolic adaptations that take place in obese people impair the normal release and breakdown of fatty acids from adipose tissue.  Simultaneously, the body becomes much more efficient in diverting calories from food and storing them as fat.

About Beloranib

Beloranib is the first compound in its class that works by targeting a key enzyme called MetAP2 that controls the production and utilization of fatty acids.  Inhibitors of MetAP2 reduce the production of new fatty acid molecules by the liver and help to convert stored fats into useful energy.  Beloranib is being developed as a twice-weekly subcutaneous injection for severe obesity.  Zafgen holds exclusive worldwide rights (exclusive of Korea) for development and commercialization of beloranib.  The company licensed beloranib from CKD Pharma.

About Zafgen, Inc.

Zafgen is an innovative company dedicated to addressing the unmet need of severely obese patients by bringing beloranib, a first
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rigel Announces Third Quarter 2012 Financial Results
2. Jazz Pharmaceuticals Announces Support for National Campaign Designed to Curb Prescription Drug Abuse
3. Mindray Medical Announces Top Management Change
4. Cepheid Announces Executive Vice President Emerging Markets
5. Cardica Announces Fiscal 2013 First Quarter Financial Results
6. PDL BioPharma Announces Third Quarter 2012 Financial Results
7. DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
8. Global Green, Inc. Announces DTC Eligibility
9. Psychemedics Corporation Announces 3rd Quarter Earnings
10. Medisafe 1 Technologies Announces Delay in Closing $7MM Perpetual License Sale Due to Hurricane Sandy
11. Life Sciences Entrepreneurs S.L.U. Announces the First Financing of the Antiplatelet Candidate NmC by Spanish and Swiss Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 26, 2014 Investor-Edge ... VVUS ), Horizon Pharma PLC (NASDAQ: ... and Johnson (NYSE: JNJ ), and Theravance Inc. ... companies can be accessed at: http://investor-edge.com/register . ... 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% ...
(Date:11/26/2014)... 26, 2014 Zynerba Pharmaceuticals , Inc., ... innovative transdermal synthetic cannabinoid treatments, today announced that the ... Healthcare Conference 2014. The conference will be held December ... New York . Zynerba,s Chairman and ... pm on Tuesday, December 2. To listen ...
(Date:11/26/2014)... and NEW YORK and ... As the leading distributor of market intelligence, MarketResearch.com is ... report by IQ4I Research and Consultancy focusing on the ... more about IQ4I Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . ... Pharmaceutical Ingredients Global Market – Forecast to 2020 ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3
(Date:11/28/2014)... The Alternative Health Therapies ... past five years. The industry has been buoyed ... are either alternative to conventional Western medicine or ... analyst David Whytcross, “industry revenue has been further ... health insurance membership.” Meanwhile, improving economic conditions following ...
(Date:11/28/2014)... (HealthDay News) -- Celebration can quickly turn to ... Day, experts say. Over the last decade, more ... while people were using turkey fryers, according to the ... cared for a patient who tried to deep fry ... in any circumstances," Dr. Arthur Sanford, a burn surgeon ...
(Date:11/28/2014)... Not only is the Éminence Organic Skin ... parabens and other cancer-causing agents, but they are also ... awareness programs that help in the fight against breast ... an incredible, record-breaking contribution of $30,000 through participation in ... Sweet Red Rose Whip Moisturizer and the company’s corporate ...
(Date:11/28/2014)... 28, 2014 Earlier in the ... the hugely popular, 2014 MTV Video Music Awards ... launched ground-breaking celebrity centered television advertisements directed at ... figures were estimated by Entertainment Weekly ... the spotlight on celebrities photographed by paparazzi smoking. ...
(Date:11/28/2014)... A newly released article from Community Health ... virus that will soon be spreading across the United States ... with a brief explanation of what the influenza virus is ... children under the age of 5, adults over the age ... heart and lung diseases, asthma, or diabetes, are at higher ...
Breaking Medicine News(10 mins):Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2
... Additional leadership needed to manage growthWAYNE, Pa. March 10 ... software, workflow tools and consulting services, is adding two ... line in order to best manage its growing client ... Vice President of Audit and Education Services and James ...
... 10 More physician leaders are embracing technological advances, ... them clunky and unresponsive to their needs.Those are the ... College of Physician Executives (ACPE). The findings were published ... ACPE,s journal of medical management.ACPE conducted the same survey ...
... LCAV ) today announced that following a rigorous clinical comparison ... to reduce the number of platforms at each of its ... The Company expects this will reduce annual operating expenses in ... no later than the end of the third quarter of ...
... 10, 2009 Forest Laboratories, Inc. (NYSE: FRX ... KGaA, and Merz Pharmaceuticals GmbH announced today that the U.S. ... Determination granting the full five years of patent term extension ... listed in the U.S. Food and Drug Administration Orange Book ...
... Safety Week, the spotlight shifts to the 30,000 dental assistants ... who help ensure that sedation dentistry is as safe for ... much an all-team responsibility," says Dr. Michael Silverman, national chairman ... sedation dentistry educators. , ...
... signs multi-year agreement with PureWellness to provide comprehensive employee wellness program ... ... 2009 -- PureWellness, Inc, a leading provider of online wellness solutions, ... in Plano, TX, to provide a comprehensive online wellness program for ...
Cached Medicine News:Health News:Precyse Solutions Adds Executives, Realigns Around Service Lines 2Health News:Survey Results: Health Care Technology Advances as Physician Frustration Grows 2Health News:LCA-Vision New Excimer Laser Strategy to Reduce Operating Expenses in Excess of $3 Million Annually 2Health News:LCA-Vision New Excimer Laser Strategy to Reduce Operating Expenses in Excess of $3 Million Annually 3Health News:LCA-Vision New Excimer Laser Strategy to Reduce Operating Expenses in Excess of $3 Million Annually 4Health News:USPTO Issues Notice of Final Determination for Patent Term Extension for NAMENDA(R) 2Health News:Sedation Dentistry Safety Week Spotlights the Important Role of Dental Team Members 2Health News:Sedation Dentistry Safety Week Spotlights the Important Role of Dental Team Members 3Health News:Global Leader in Information Technology Services and Business Solutions Signs Long-Term Agreement with PureWellness 2Health News:Global Leader in Information Technology Services and Business Solutions Signs Long-Term Agreement with PureWellness 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: